NASHVILLE, Tenn. / Mar 05, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 19, 2024, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Wednesday, March 20, 2024, to discuss the results and provide a business update.
Conference Call Details: |
|
Date: | Wednesday, March 20, 2024 |
Time: | 8:00 a.m. Eastern time |
Participant Dial-in: | 1-833-953-2434 (U.S.) |
Replay Dial-in (Passcode 6766979): (telephonic replay through March 27, 2024) | 1-877-344-7529 (U.S.) |
Webcast: (online replay through March 20, 2025) |
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
| Last Trade: | US$36.15 |
| Daily Change: | 0.13 0.36 |
| Daily Volume: | 207,557 |
| Market Cap: | US$1.290B |
November 13, 2024 November 12, 2024 November 07, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
